路透北京10月29日 - 中国生物制药企业--君实生物688180.SS1877.HK周四公布,三季度净亏1.7亿元人民币,同期营收同比增近三成,商业化药品销售收入增长。
该公司刊登在上交所网站的财报显示:
三季度净亏1.7亿元,上年同期净亏1.8亿元
三季度营收8.2亿元,同比增28.2%
前三季度净亏1.5亿元,营收同比增39.2%
与上年同期相比商业化药品销售收入增长,导致前三季度营收增长
与上年同期相比,前三季公司商业化药品销售收入增长,同时经营质量继续优化,亏损显著缩窄
路透北京10月29日 - 中国生物制药企业--君实生物688180.SS1877.HK周四公布,三季度净亏1.7亿元人民币,同期营收同比增近三成,商业化药品销售收入增长。
该公司刊登在上交所网站的财报显示:
三季度净亏1.7亿元,上年同期净亏1.8亿元
三季度营收8.2亿元,同比增28.2%
前三季度净亏1.5亿元,营收同比增39.2%
与上年同期相比商业化药品销售收入增长,导致前三季度营收增长
与上年同期相比,前三季公司商业化药品销售收入增长,同时经营质量继续优化,亏损显著缩窄
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.